CPC Class C12Q

The present invention relates to a Lactuca sativa seed designated 45-227 RZ. The present invention also relates to a Lactuca sativa plant produced by growing the 45-227 RZ seed. The invention further relates to methods for producing the lettuce cultivar, represented by lettuce variety 45-227 RZ.

The invention relates to the soybean variety designated 01068088. Provided by the invention are the seeds, plants and derivatives of the soybean variety 01068088. Also provided by the invention are tissue cultures of the soybean variety 01068088 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety 01068088 with itself or another soybean variety and plants produced by such methods.

A method is provided of targeted genome editing of an animal using site specific homologous integration. A composition comprising a single stranded oligonucleotide or double stranded nucleic acid molecule comprising a nucleic acid molecule of interest and sequences flanking a target locus cleavage site is injected into the zygote of an animal along with a nuclease and a guide nucleic acid molecule that targets the nuclease to a target locus. The composition is injected into the zygote after fertilization and prior to formation of a nucleus. The nucleic acid molecule of interest is recombined into the genome with high efficiency. The process allows for integration of nucleic acid molecules into the genome of animals in which the pronuclei cannot be visually observed during injection.

Systems and methods of use for continuous analyte measurement of a host's vascular system are provided. In some embodiments, a continuous glucose measurement system includes a vascular access device, a sensor and sensor electronics, the system being configured for insertion into communication with a host's circulatory system.

A platform for ex vivo isolation, production, and formulation of genetically-modified cells is described. The platform utilizes a software-enabled point-of-care and/or portable device making gene therapy more widely available.

The present invention relates to a method for generating semi-mature dendritic cells by treating immature dendritic cells with the auto-antigen, cytokine, and PGE2 as a target for the treatment of autoimmune diseases, particularly rheumatoid arthritis, in which the levels of NR4A2 and/or UBASH3B at gene or protein are increased more than 2-fold compared to the immature dendritic cells In addition, the present invention relates to a cell therapeutic agent for treating or preventing autoimmune diseases, containing the semi-mature dendritic cells as an active ingredient. The present invention increases the therapeutic efficacy on rheumatoid arthritis retaining responsiveness to the same auto-antigen that being used for preparing semi-mature dendritic cells, thereby enabling cell therapy.